Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)

NCT03203473 is registered in ClinicalTrials.gov with Toni Choueiri, MD as lead sponsor.

NCT NCT03203473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03203473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)
Lead sponsor
Toni Choueiri, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 26, 2017
Completion date
December 28, 2026
Enrollment
85 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

renal cancer